Dwibedi et al. carry out a randomized controlled trial to evaluate whether subgroups of patients with diabetes could receive the greatest metabolic benefit from novel anti-diabetic drugs.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ahlqvist, E. et al. Lancet Diabetes Endocrinol. 6, 361–369 (2018).
Zou, X., Zhou, X., Zhu, Z. & Ji, L. Lancet Diabetes Endocrinol. 7, 9–11 (2019).
Mansour Aly, D. et al. Nat. Genet. 53, 1534–1542 (2021).
Zaghlool, S. B. et al. Nat. Commun. 13, 7121 (2022).
Zaharia, O. P. et al. Lancet Diabetes Endocrinol. 7, 684–694 (2019).
Zou, X. et al. Diabetologia 65, 1424–1435 (2022).
Dennis, J. M., Shields, B. M., Henley, W. E., Jones, A. G. & Hattersley, A. T. Lancet Diabetes Endocrinol. 7, 442–451 (2019).
Raverdy, V. et al. Lancet Diabetes Endocrinol. 10, 167–176 (2022).
Dwibedi, C. et al. Nat. Metab. https://doi.org/10.1038/s42255-023-00943-3 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Zou, X., Ji, L. A second step towards precision medicine in diabetes. Nat Metab 6, 10–11 (2024). https://doi.org/10.1038/s42255-023-00950-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s42255-023-00950-4